SEPTInvestingStart Free

ALLO 8-K: SEC filing

Allogene Therapeutics

Filed with the SEC on · accession 0001628280-26-071040

ALLO filed a 8-K (current report) with the SEC on Nov 5, 2026. Allogene Therapeutics reported Q3 2026 financial results with $388.9 million in cash and provided business updates on its ALPHA3 pivotal trial for cema-cel in large B-cell lymphoma and the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease. The stock moved -8.4% by the first close after the filing.

Summary of the filing

Allogene Therapeutics reported Q3 2026 financial results with $388.9 million in cash and provided business updates on its ALPHA3 pivotal trial for cema-cel in large B-cell lymphoma and the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease. The company also announced the appointment of Rocio Manghani as Vice President, Market Access, Evidence & Strategy.

For details, click here →How to read a 8-K →

Key details

Cash, cash equivalents and investments as of September 30, 2026$388.9M
IssuerAllogene Therapeutics, Inc.
President and chief executive officerZachary Roberts
Vice president, market access, evidence & strategyRocio Manghani

How ALLO stock reacted

Close before

$1.19

Nov 4, 2026

First close after

-8.40%

$1.09

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ALLO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ALLO?

Click here

Frequently asked questions

What did ALLO file with the SEC on Nov 5, 2026?

ALLO filed a 8-K (SEC filing). Allogene Therapeutics reported Q3 2026 financial results with $388.9 million in cash and provided business updates on its ALPHA3 pivotal trial for cema-cel in large B-cell lymphoma and the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease. The company also announced the appointment of Rocio Manghani as Vice President, Market Access, Evidence & Strategy.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did ALLO stock react to this filing?

ALLO closed at $1.19 before the filing and $1.09 on Nov 5, 2026 (-8.40%).

Other ALLO SEC filings

Get alerts when ALLO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ALLO overviewALLO analysisALLO newsLatest SEC filings